What Are the Projections for the Global End Stage Renal Disease (ESRD) Drug Market Size and Growth Rates?
The end stage renal disease (ESRD) drug market size has grown rapidly in recent years. It will grow from $131.41 billion in 2024 to $149.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies. Additionally, the market size is expected to see rapid growth in the next few years, reaching $268.44 billion in 2029 at a CAGR of 15.7%, due to emerging therapies, drug innovations, increasing healthcare expenditure, and rising global burden of chronic kidney diseases.
Get Your Free Sample of The Global End Stage Renal Disease (ESRD) Drug Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
What Are the Key Growth Drivers for the End Stage Renal Disease (ESRD) Drug Market?
Rising cases of obesity and diabetes are key growth drivers for the end-stage renal disease (ESRD) drug market. Obesity and diabetes are major health concerns that increase the risk of end stage renal disease. Managing these conditions can improve patients’ general health and well-being, leading to weight reduction and improved blood sugar control. For instance, the number of obese people is expected to rise to 892 million in 2025 and then to 1,025 million in 2030. Similarly, it is estimated that by 2030, the number of people in the UK with diabetes could reach 5.5 million, impacting nearly 9% of the population.
What Are the Major Segments Within the Global End Stage Renal Disease (ESRD) Drug Market?
– By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
– By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
– By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
– By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Order your report now for swift delivery:
https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report
Who Are the Major Players Operating in the End Stage Renal Disease (ESRD) Drug Market?
Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA are some of the major companies operating in the end stage renal disease (ESRD) drug market.
What Are the Emerging Trends in the End Stage Renal Disease (ESRD) Drug Market?
Product innovations are gaining popularity in the market. For instance, in April 2022, GlaxoSmithKline PLC announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the possible treatment of patients with chronic kidney disease anemia (CKD).
Which Region Will Witness the Fastest Growth in the End Stage Renal Disease (ESRD) Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024, with other regions including Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa also contributing significantly to the market size.
What Does The End Stage Renal Disease (ESRD) Drug Market Report 2025 Offer?
End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person’s kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD). The End Stage Renal Disease (ESRD) Drug Market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9437
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model